Your AI-Trained Oncology Knowledge Connection!
Adjuvant treatment with the combination of atezolizumab and bevacizumab demonstrated a statistically significant improvement in recurrence-free survival compared with active surveillance in patients with early-stage hepatocellular carcinoma at high risk of disease recurrence.
The Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center are pleased to announce the hiring of Lucia Borriello, PhD, as an assistant professor in the Department of Cancer and Cellular Biology at Temple.
The Signatera molecular residual disease test was able to detect patients with stage II to IV colorectal cancer who were at an increased risk for recurrence and predict which patients were most likely to benefit from adjuvant chemotherapy.
First-line ibrutinib plus prednisone did not improve response rates compared with placebo plus prednisone in patients with chronic graft-vs-host disease, failing to meet the primary end point of the phase 3 iNTEGRATE trial.
Carsten Niemann, MD, PhD, discusses the significance of new data from the GLOW trial, the potential relationship between treatment regimen, minimal residual disease status, and survival outcomes, and the importance of research into precision medicine approaches in chronic lymphocytic leukemia.
Tanios S. Bekaii-Saab, MD, FACP, expands on key data reported from the MOUNTAINEER trial, the potential effects of this regimen’s approval on the current treatment landscape, and the continued investigation of this and other targeted approaches in metastatic colorectal cancer.
With three years to go, C. Ola Landgren, MD, PhD, is on track to establish a “top three” U.S. myeloma program within five years, with the announcement of the new, dedicated Myeloma Research Institute within Sylvester Comprehensive Cancer Center.
Olutasidenib has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a recommended targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation.
Perioperative treatment with the combination of toripalimab plus platinum-containing doublet chemotherapy, followed by toripalimab monotherapy as consolidation therapy after surgery, significantly extended event-free survival compared with chemotherapy plus placebo in patients with operable NSCLC.
Sometimes, clinicians do not acknowledge how patients' values and beliefs influence how they ascribe meaning to their illness, how they prefer to receive information, and how they make decisions until the end-of-life stage, leading to misunderstandings between clinicians and patients.
Virginia F. Borges, MD, MMSc, and colleagues highlight updates across the breast cancer landscape, including key updates from the 2022 SABCS.
Patients who received MRI-guided stereotactic body radiotherapy for prostate cancer experienced fewer moderate acute physician-scored genitourinary and gastrointestinal adverse effects compared with those who received computed tomography–guided stereotactic body radiotherapy.
John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses previous research with anti-HER2 TKIs in HER2-positive breast cancer, expanded on key follow-up data from this phase 2 trial, and emphasized the importance of continued investigation into this underutilized combination.
The PIM1 kinase inhibitor TP-3654 was well tolerated and showcased preliminary signs of activity, including spleen volume reduction, symptom improvement, and broad cytokine reduction, in patients with myelofibrosis who were previously treated with or were ineligible for a JAK inhibitor.
Amandeep Salhotra, MD, provides insight on the data with Orca-Q shared during the 2022 ASH Annual Meeting.
The Association of Community Cancer Centers is announcing the release of a new tool intended to facilitate education and adoption of new clinical and technological advancements in diagnosis, staging, and treatment of cancer.
Saketh Guntupalli, MD, highlights data supporting PARP inhibitors as the standard-of-care frontline therapy, strategies for the management of PARP-related toxicities, and the importance of testing for HRD and BRCA status in patients with ovarian cancer.
Similar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.
Tusamitamab ravtansine, an antibody-drug conjugate that targets CEACAM5, could expand the treatment armamentarium for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.
The addition of daratumumab to lenalidomide and dexamethasone led to a 27% reduction in the risk of death compared with Rd alone in patients with relapsed/refractory multiple myeloma.
Neoadjuvant treatment with anti–PD-1 inhibitors induced high rates of complete response and reduced recurrence rates, according to a retrospective analysis of patients with localized mismatch repair-deficient or microsatellite instability–high colorectal cancer.
The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.
New research including Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis indicates it’s both possible and helpful to get cancer patients who smoke into evidence-based tobacco-treatment programs as part of their cancer care.
R-DHAP plus high-dose cytarabine-containing myeloablative radiochemotherapy conditioning and autologous stem cell transplant demonstrated sustained time to treatment failure and overall survival benefits vs R-CHOP plus standard myeloablative radiochemotherapy and ASCT in patients with mantle cell lymphoma aged 65 years and younger.
Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.
Axicabtagene ciloleucel continued to elicit improved progression-free survival and overall response rates in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Patients with B-cell malignancies who were intolerant to acalabrutinib experienced a longer treatment duration when subsequently receiving zanubrutinib.
First-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin elicited responses in patients with mantle cell lymphoma, according to preliminary results from the phase 2 CHESS trial.
A doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressing solid tumors.
Emma Searle, PhD, provides an overview of findings from the MajesTEC-2 trial in patients with relapsed/refractory multiple myeloma, elaborates on the safety of teclistamab plus daratumumab and lenalidomide, and discusses the next steps for evaluating the combination.
